Document is current
Any future updates will be listed below
-
Authors
Landfeldt, Erik http://orcid.org/0000-0002-5758-7151
Alemán, Alberto
Abner, Sophia
Zhang, Rongrong http://orcid.org/0000-0002-1228-9345
Werner, Christian http://orcid.org/0000-0002-6139-7473
Tomazos, Ioannis http://orcid.org/0000-0003-0290-4583
Lochmüller, Hanns
Quinlivan, Ros M.
Wahbi, Karim
-
Funding
Funding for this research was provided by:
PTC Therapeutics
- License Information
-
More Information
Article History
Received: 15 November 2023
Accepted: 18 September 2024
First Online: 28 September 2024
Declarations
:
: Not applicable.
: Not applicable.
: Dr Alemán reports being sub-investigator of clinical trials in DMD sponsored by Pfizer and Reveragen, and receiving a research grant from PTC. Ms Zhang, Dr Werner, and Dr Tomazos are employees of PTC Therapeutics and may own stock/options in the company. Professor Lochmüller reports being principal investigator of clinical trials in DMD sponsored by Pfizer, PTC Therapeutics, Santhera, Sarepta, and Reveragen. Professor Quinlivan reports having received honoraria for teaching, consultancy, and iDMC membership from PTC therapeutics, Sanofi-Genzyme, Santhera, Sarepta, TRiNDS, and Astellas, as well as research and trial funding from PTC therapeutics, Santhera, and MDUK. Professor Wahbi reports having received honoraria for teaching and consultancy from PTC therapeutics, Sarepta, and Pfizer. The remaining authors have no conflicts of interest.
